Effectiveness of sacubitril-valsartan in patients with cancer therapy-related cardiac dysfunction (CTRCD): a systematic review of clinical and preclinical studies
Journal article
Duraes, Andre R, Bitar, Yasmin S, Neto, Mansueto G, Mesquita, Evandro T, Chan, Jeffrey S, Tse, Gary, Liu, Tong, Boochi, Edimar A, Biondi-Zoccai, Giuseppe and Roever, Leonardo 2022. Effectiveness of sacubitril-valsartan in patients with cancer therapy-related cardiac dysfunction (CTRCD): a systematic review of clinical and preclinical studies. Minerva Medica. https://doi.org/10.23736/S0026-4806.22.08029-6
Authors | Duraes, Andre R, Bitar, Yasmin S, Neto, Mansueto G, Mesquita, Evandro T, Chan, Jeffrey S, Tse, Gary, Liu, Tong, Boochi, Edimar A, Biondi-Zoccai, Giuseppe and Roever, Leonardo |
---|---|
Abstract | Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment. However, there are very limited data on the efficacy of sacubitril/valsartan in the prevention and treatment of cardiotoxicity. This systematic review aimed to evaluate the potential benefit of sacubitril/valsartan in patients with CTRCD. The databases included MEDLINE, Embase, LILACS, Scopus and Cochrane Central up to January 20, 2022. All pre-clinical and clinical studies including observational studies (cohorts, case-control, cross-sectional and case reports) that used sacubitril/valsartan for prevention or treatment of CTRCD. The primary effectiveness endpoints was CTRCD, defined as a clinically significant change in left ventricular ejection fraction (LVEF) at the end of the follow-up. And after applying the eligibility criteria, 12 articles (9 in humans and 3 preclinical studies) were included in this systematic review. The 3 preclinical studies demonstrated beneficial effects in preventing, attenuating and/or delaying the onset of myocardial damage at the cellular level, ventricular dysfunction and remodeling. Regardind human studies, most of them were composed of case reports. The largest study consisted of a retrospective multicentric cohort with 64 patients. All clinical studies have demonstrated that used Sac/Val in human showed a significant increase in LVEF, and when reported, a reduction in left ventricular volume and NT-proBNP (or BNP). Randomized clinical trials are needed to confirm this hypothesis. |
Keywords | Sacubitril/Valsartan; Heart failure; Cardiotoxicity |
Year | 2022 |
Journal | Minerva Medica |
Publisher | Edizioni Minerva Medica |
ISSN | 1827-1669 |
Digital Object Identifier (DOI) | https://doi.org/10.23736/S0026-4806.22.08029-6 |
Official URL | https://www.minervamedica.it/en/journals/minerva-medica/article.php?cod=R10Y9999N00A22021405 |
Publication dates | |
Online | 14 Feb 2022 |
Publication process dates | |
Deposited | 28 Feb 2022 |
Output status | Published |
Permalink -
https://repository.canterbury.ac.uk/item/9087x/effectiveness-of-sacubitril-valsartan-in-patients-with-cancer-therapy-related-cardiac-dysfunction-ctrcd-a-systematic-review-of-clinical-and-preclinical-studies
118
total views0
total downloads2
views this month0
downloads this month